Ocugen's Stargardt Trial Shows Negative Interim Effect, Stock Drops 14%
OCGN is trading near its 52-week low of $1.01 (13% above the low) on elevated volume (3.0× avg).
Summary
Ocugen disclosed that an independent Data Monitoring Committee observed a negative treatment effect in an interim analysis of its Phase 2/3 trial for OCU410ST, a gene therapy for Stargardt disease. The analysis, based on 26 subjects who completed eight-month assessments, showed the treatment may be worsening atrophic lesion size. The DMC noted futility could be considered but recommended continuing the trial to collect full eight-month data for the entire study population. This is a significant setback for a lead pipeline candidate, especially given the company's going concern warning and upcoming September 21 shareholder vote to authorize shares for convertible note settlement. The stock fell nearly 14%, its worst single-day decline since May. The company plans to submit a U.S. marketing application in mid-2027 following a top-line readout expected in Q2 2027, but today's data raises substantial doubt about the program's viability.
At the time of this announcement, OCGN was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $386.6M. The 52-week trading range was $1.01 to $2.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.